PACB
What one share of Pacific Biosciences of California holds
Laboratory Analytical Instruments
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.
Pacific Biosciences of California’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.52 |
|---|---|
| Profit | −$0.43 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.40 |
| Cash and investments | $0.20 |
| Debt | $2.07 |
| Book value | −$0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.02 | −$0.83 | $0.09 | −$0.85 | $0.00 | $0.91 |
| 2017 | $0.88 | −$0.87 | $0.10 | −$0.74 | $0.00 | $0.74 |
| 2018 | $0.58 | −$0.76 | $0.01 | −$0.51 | $0.00 | $0.76 |
| 2019 | $0.60 | −$0.55 | $0.02 | −$0.53 | $0.00 | $0.36 |
| 2020 | $0.45 | $0.17 | $0.01 | $0.11 | $0.00 | $1.74 |
| 2021 | $0.64 | −$0.89 | $0.03 | −$0.57 | $0.00 | $3.58 |
| 2022 | $0.57 | −$1.40 | $0.07 | −$1.25 | $0.00 | $2.49 |
| 2023 | $0.79 | −$1.21 | $0.03 | −$1.06 | $0.00 | $2.62 |
| 2024 | $0.53 | −$1.59 | $0.02 | −$0.74 | $0.00 | $1.72 |
| 2025 | $0.53 | −$1.82 | $0.01 | −$0.38 | $0.00 | $0.02 |